ANXA2 and metabolic dysfunction-associated steatohepatitis: In addition, overexpression of Anxa2 significantly aggravated liver pathological changes in NASH mice, while such a promotion effect could be significantly reversed by the inhibition of Caspase-1 activation with VX-765 (Fig. 8B).